Rhoen Klinikum (RHK) H1 2025 earnings summary

Executive summary

• Revenues rose 7.5% year-over-year to €833.5 million, driven by higher inpatient and semi-inpatient treatments and increased state base rates.

• EBITDA remained solid at €46.7 million despite the end of energy cost relief and rising personnel and supply costs.

• Consolidated profit declined 28.6% to €14.7 million due to lower finance result and the expiry of government support.

• Equity ratio remains strong at 71.3%, reflecting a stable financial position.

• The company maintained robust performance amid sector challenges and ongoing hospital reform in Germany.

Financial highlights

• Revenues: €833.5 million (up 7.5% year-over-year); EBITDA: €46.7 million (down 4.9%); EBIT: €17.3 million (down 7.0%).

• Consolidated profit: €14.7 million (down 28.6%); EPS: €0.21 (down from €0.30).

• Net liquidity at €194.1 million, down from €259.9 million at year-end 2024.

• Cash used in operating activities: €25.6 million (vs. €40.3 million generated in prior year period).

• Investments in intangible assets and property, plant, and equipment totaled €35.1 million.

Outlook and guidance

• Full-year 2025 revenue expected at €1.7 billion, within a ±5% range.

• EBITDA guidance maintained at €110–125 million.

• Moderate increases in case numbers and cost weights anticipated.

• Outlook subject to uncertainties from global crises, inflation, supply chain issues, and regulatory changes.